imatinib mesylate + mycophenolate mofetil

This is a combination therapy consisting of imatinib mesylate and mycophenolate mofetil. Imatinib mesylate is a small molecule tyrosine kinase inhibitor that targets BCR-ABL, c-Kit (stem cell factor receptor), and platelet-derived growth factor receptors (PDGFR), thereby inhibiting proliferation and inducing apoptosis in malignant cells. Mycophenolate mofetil is an immunosuppressant prodrug of mycophenolic acid that inhibits inosine monophosphate dehydrogenase (IMPDH), leading to depletion of guanine nucleotides required for lymphocyte proliferation. The combination has been studied primarily for steroid-refractory chronic graft-versus-host disease (cGVHD) with sclerotic/fibrotic features, showing promising efficacy and acceptable toxicity in early-phase clinical trials[1][2][9]. Preclinical studies also suggest synergy between these agents in BCR-ABL–positive leukemias due to complementary mechanisms affecting cell signaling and survival[3][4].

Other names

imatinib + MMFimatinib mesylate plus mycophenolate mofetil